<DOC>
	<DOC>NCT00472927</DOC>
	<brief_summary>To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).</brief_summary>
	<brief_title>Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens, Conjugated (USP)</mesh_term>
	<criteria>Healthy, postmenopausal women, aged 35 to 70 years Spontaneous amenorrhea for at least 12 months (no FSH required) or spontaneous amenorrhea for at least 6 months (FSH level ≥38 mIU/mL); spontaneous amenorrhea must have begun by the age of 55 BMI in the range of 18 to 35 kg/m2 History or presence of hypertension (&gt;139 mm Hg systolic or &gt;89 mm Hg diastolic) History of drug allergy to conjugated estrogens (CE) or selective estrogen receptor modulators (SERMs) Use of prescription or investigatioanl drugs within 30 days before test article administration</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>